Exscientia Announced Two Abstracts To Be Presented At The Upcoming European Society For Medical Oncology Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Exscientia announced that two abstracts will be presented at the European Society for Medical Oncology Congress 2023. The abstracts demonstrate the preclinical efficacy of LSD1 inhibitor in primary AML samples and the potential of LSD1 inhibitor with AML standard of care therapies. They also show tumor growth inhibition through MALT1 in monotherapy and combination while lowering bilirubin toxicity risk.
October 16, 2023 | 11:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exscientia's announcement of presenting two abstracts at the ESMO Congress 2023 could potentially boost investor confidence in the company's research and development capabilities.
The announcement of the presentation of two abstracts at a prestigious medical congress indicates that Exscientia's research is being recognized by the medical community. This could potentially boost investor confidence in the company's research and development capabilities, leading to a positive impact on the company's stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100